GARP: Ile18-Asn628, with C-terminal His Latent TGF-β1: Leu30-Ser390
80-93kDa GARP(Reducing), 35-50kDa LAP(Reducing), 10-14kDa mature TGF-β1 (Reducing)
PBS, pH7.4.
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
1. Alessandra Metelli, Mohammad Salem, Caroline H Wallace, Bill X Wu, Anqi Li. Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer. J Hematol Oncol. 2018 Feb 20;11(1):24.
GARP (glycoprotein-A repetitions predominant) is a type I transmembrane cell surface docking receptor for latent transforming growth factor-β (TGF-β) that is abundantly expressed on regulatory T lymphocytes and platelets. By binding to LTGF-β, GARP acts as a docking receptor that concentrates LTGF-β on the cell surface and enhances its final activation. The function of GARP has been extensively studied on regulatory T lymphocytes (Tregs), where it complexes with αVβ8 integrins to release active TGF-β from the surface of the cells. Via this function, GARP was shown to be involved in enhancing the suppressive phenotype of Tregs and in maintaining Treg-mediated peripheral tolerance.
2μg (R: reducing condition.
The purity of GARP&Latent TGF-β1 Heterotrimer His Tag, Mouse is more than 95%.
Immobilized GARP&Latent TGF-β1 Heterotrimer His Tag Protein, Mouse (Cat. No. UA010802) at 2μg/mL (100μL/well) can bind TGFBR2 Fc Chimera Protein, Mouse (Cat. No. UA010646) with EC50 of 3.32-4.89 ng/ml.